Overview

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Status:
RECRUITING

Trial end date:
2027-12-15

Target enrollment:

Participant gender:

Summary

This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other places is the body (metastatic). Bipolar androgen therapy is the regulation of testosterone between castration levels (lower than what would be normally present) and supraphysiological levels (amounts greater than normally found in the body). This may suppress cancer cell growth, which reduces prostate-specific antigen (PSA) levels and may delay cancer progression.

Phase:

PHASE1

Details

Lead Sponsor:

Roswell Park Cancer Institute

Treatments:

Biopsy
Leuprolide
luprolide acetate gel depot
Magnetic Resonance Spectroscopy
Methyltestosterone
testosterone 17 beta-cypionate
Testosterone Propionate